Phase I Clinical Trial of Recombinant Viscumin (rVISCUMIN, rMISTLETOE LECTIN, rML) Administered Twice Weekly by the Subcutanous Route in Patients With Solid Tumors After Failure of Standard Therapy
Latest Information Update: 16 Jul 2015
At a glance
- Drugs Aviscumine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 14 Oct 2011 New trial record